Literature DB >> 11524458

Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor.

G Avila1, R T Dirksen.   

Abstract

Central core disease (CCD) is a human myopathy that involves a dysregulation in muscle Ca(2)+ homeostasis caused by mutations in the gene encoding the skeletal muscle ryanodine receptor (RyR1), the protein that comprises the calcium release channel of the SR. Although genetic studies have clearly demonstrated linkage between mutations in RyR1 and CCD, the impact of these mutations on release channel function and excitation-contraction coupling in skeletal muscle is unknown. Toward this goal, we have engineered the different CCD mutations found in the NH(2)-terminal region of RyR1 into a rabbit RyR1 cDNA (R164C, I404M, Y523S, R2163H, and R2435H) and characterized the functional effects of these mutations after expression in myotubes derived from RyR1-knockout (dyspedic) mice. Resting Ca(2)+ levels were elevated in dyspedic myotubes expressing four of these mutants (Y523S > R2163H > R2435H R164C > I404M RyR1). A similar rank order was also found for the degree of SR Ca(2)+ depletion assessed using maximal concentrations of caffeine (10 mM) or cyclopiazonic acid (CPA, 30 microM). Although all of the CCD mutants fully restored L-current density, voltage-gated SR Ca(2)+ release was smaller and activated at more negative potentials for myotubes expressing the NH(2)-terminal CCD mutations. The shift in the voltage dependence of SR Ca(2)+ release correlated strongly with changes in resting Ca(2)+, SR Ca(2)+ store depletion, and peak voltage-gated release, indicating that increased release channel activity at negative membrane potentials promotes SR Ca(2)+ leak. Coexpression of wild-type and Y523S RyR1 proteins in dyspedic myotubes resulted in release channels that exhibited an intermediate degree of SR Ca(2)+ leak. These results demonstrate that the NH(2)-terminal CCD mutants enhance release channel sensitivity to activation by voltage in a manner that leads to increased SR Ca(2)+ leak, store depletion, and a reduction in voltage-gated Ca(2)+ release. Two fundamentally distinct cellular mechanisms (leaky channels and EC uncoupling) are proposed to explain how altered release channel function caused by different mutations in RyR1 could result in muscle weakness in CCD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524458      PMCID: PMC2229502          DOI: 10.1085/jgp.118.3.277

Source DB:  PubMed          Journal:  J Gen Physiol        ISSN: 0022-1295            Impact factor:   4.086


  42 in total

1.  Evidence for linkage of the central core disease locus to the proximal long arm of human chromosome 19.

Authors:  K Kausch; F Lehmann-Horn; M Janka; B Wieringa; T Grimm; C R Müller
Journal:  Genomics       Date:  1991-07       Impact factor: 5.736

2.  Abnormal ryanodine receptor channels in malignant hyperthermia.

Authors:  M Fill; R Coronado; J R Mickelson; J Vilven; J J Ma; B A Jacobson; C F Louis
Journal:  Biophys J       Date:  1990-03       Impact factor: 4.033

3.  A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease.

Authors:  P J Lynch; J Tong; M Lehane; A Mallet; L Giblin; J J Heffron; P Vaughan; G Zafra; D H MacLennan; T V McCarthy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 4.  Mitochondrial calcium transport: physiological and pathological relevance.

Authors:  T E Gunter; K K Gunter; S S Sheu; C E Gavin
Journal:  Am J Physiol       Date:  1994-08

5.  Dyspedic mouse skeletal muscle expresses major elements of the triadic junction but lacks detectable ryanodine receptor protein and function.

Authors:  E D Buck; H T Nguyen; I N Pessah; P D Allen
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

6.  Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.

Authors:  J Tong; H Oyamada; N Demaurex; S Grinstein; T V McCarthy; D H MacLennan
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

7.  A mutation in the human ryanodine receptor gene associated with central core disease.

Authors:  Y Zhang; H S Chen; V K Khanna; S De Leon; M S Phillips; K Schappert; B A Britt; A K Browell; D H MacLennan
Journal:  Nat Genet       Date:  1993-09       Impact factor: 38.330

8.  Slow calcium current is not reduced in malignant hyperthermic porcine myotubes.

Authors:  E M Gallant; E M Balog; K G Beam
Journal:  Muscle Nerve       Date:  1996-04       Impact factor: 3.217

9.  Excitation-contraction coupling in pigs heterozygous for malignant hyperthermia.

Authors:  E M Gallant; L R Lentz
Journal:  Am J Physiol       Date:  1992-02

10.  Porcine malignant hyperthermia: genotype and contractile threshold of immature muscles.

Authors:  E M Gallant; R C Jordan
Journal:  Muscle Nerve       Date:  1996-01       Impact factor: 3.217

View more
  55 in total

1.  Central core disease mutations R4892W, I4897T and G4898E in the ryanodine receptor isoform 1 reduce the Ca2+ sensitivity and amplitude of Ca2+-dependent Ca2+ release.

Authors:  Guo Guang Du; Vijay K Khanna; Xinghua Guo; David H MacLennan
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

2.  Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.

Authors:  Jose Miguel Eltit; Roger A Bannister; Ong Moua; Francisco Altamirano; Philip M Hopkins; Isaac N Pessah; Tadeusz F Molinski; Jose R López; Kurt G Beam; Paul D Allen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

Review 3.  Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels.

Authors:  Silvia G Priori; Carlo Napolitano
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

4.  Skeletal and cardiac ryanodine receptors exhibit different responses to Ca2+ overload and luminal ca2+.

Authors:  Huihui Kong; Ruiwu Wang; Wenqian Chen; Lin Zhang; Keyun Chen; Yakhin Shimoni; Henry J Duff; S R Wayne Chen
Journal:  Biophys J       Date:  2007-01-26       Impact factor: 4.033

Review 5.  Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre.

Authors:  F Lehmann-Horn; K Jurkat-Rott; R Rüdel
Journal:  Acta Myol       Date:  2008-12

6.  Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice.

Authors:  Marco Dainese; Marco Quarta; Alla D Lyfenko; Cecilia Paolini; Marta Canato; Carlo Reggiani; Robert T Dirksen; Feliciano Protasi
Journal:  FASEB J       Date:  2009-02-23       Impact factor: 5.191

7.  A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility.

Authors:  Carlos A Ibarra Moreno; Natalia Kraeva; Elena Zvaritch; Lourdes Figueroa; Eduardo Rios; Leslie Biesecker; Filip Van Petegem; Philip M Hopkins; Sheila Riazi
Journal:  Br J Anaesth       Date:  2020-08-27       Impact factor: 9.166

8.  Characterization and temporal development of cores in a mouse model of malignant hyperthermia.

Authors:  Simona Boncompagni; Ann E Rossi; Massimo Micaroni; Susan L Hamilton; Robert T Dirksen; Clara Franzini-Armstrong; Feliciano Protasi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

9.  Effects of ryanoids on spontaneous and depolarization-evoked calcium release events in frog muscle.

Authors:  Chiu Shuen Hui; Henry R Besch; Keshore R Bidasee
Journal:  Biophys J       Date:  2004-07       Impact factor: 4.033

10.  A malignant hyperthermia-inducing mutation in RYR1 (R163C): consequent alterations in the functional properties of DHPR channels.

Authors:  Roger A Bannister; Eric Estève; José M Eltit; Isaac N Pessah; Paul D Allen; José R López; Kurt G Beam
Journal:  J Gen Physiol       Date:  2010-05-17       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.